ABSTRACT
Objective:To investigate the clinical efficacy and safety of Xiaoaiping injection combined with chemotherapy in treatment of non-small cell lung cancer (NSCLC) patients.Methods:Based on LinkDoc database, a total of 1 144 patients first diagnosed as stage Ⅲ B-Ⅳ NSCLC in 4 medical centers including Henan Cancer Hospital from 2014 to 2018 were enrolled. The baseline data of included patients was used to make propensity score matching. The patients were divided into the experimental group (Xiaoaiping injection combined with chemotherapy) and the control group (chemotherapy alone), 572 cases in each group. The objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), time to progression (TTP) and adverse reactions of the two groups were observed and compared. Results:Based on the statistical results of patients with records of efficacy evaluation, the ORR of the experimental group and the control group was 26.54% (86/324) and 26.07% (79/303), respectively, and there was no statistically significant difference ( χ2 = 0.02, P = 0.894); the DCR of both groups was 61.42% (199/324) and 62.38% (189/303), respectively, and there was no statistically significant difference ( χ2 = 0.06, P = 0.805). The median OS time of the experimental group and the control group was 21.2 months and 16.5 months, respectively, and there was a statistically significant difference ( χ2 = 7.53, P = 0.006). The median PFS time was 9.3 months and 8.9 months, respectively, and there was no statistically significant difference ( χ2 = 2.25, P = 0.134). The median TTP was 1.8 months (1.2 months, 5.1 months) and 1.7 months (1.2 months, 5.8 months), respectively, and there was a statistically significant difference ( Z = 3.89, P = 0.049). The incidence of bone marrow suppression was 75.52% (432/572) and 64.51% (369/572),respectively in the experimental group and the control group, and there was a statistically significant difference ( χ2 = 16.53, P <0.001); the incidence of liver dysfunction was 39.86% (228/572) and 29.55% (169/572), respectively, and there was a statistically significant difference ( χ2 = 13.43, P < 0.001); the incidence of abnormal kidney function was 2.45% (14/572) and 3.15% (18/572), respectively, and there was no statistically significant difference ( χ2 = 0.51, P = 0.473). Conclusions:Xiaoaiping injection combined with chemotherapy can prolong the survival time of patients with advanced NSCLC. It is necessary to pay attention to the potential risks of bone marrow suppression and liver damage.